Ardelyx

Historical price data

Ardelyx is a mission-driven biotech focused on discovering, developing, and commercializing first-in-class, gut-targeted medicines for significant unmet needs in cardiorenal and metabolic diseases. The company has successfully transitioned to a commercial entity with two approved products derived from its core NHE3 inhibition platform, XPHOZAH® and IBSRELA®, and maintains a broad pipeline of 27 candidates. Its strategy leverages a unique mechanism of action to avoid systemic side effects, supported by strategic ex-U.S. partnerships and a dedicated commercial effort to capture value in large, underserved markets.

Proprietary platform focused on targeting ion transporters and receptors in the gastrointestinal tract, with core expertise in the selective inhibition of the NHE3 (sodium/hydrogen exchanger isoform 3) transporter to treat systemic cardiorenal and metabolic diseases.

In hyperphosphatemia, Ardelyx competes with traditional phosphate binders and newer agents, differentiating via its novel, non-binder NHE3 mechanism. In IBS-C, it faces established secretagogues like linaclotide, competing on rapid onset of action for both constipation and pain. Its core platform expertise in gut-mediated therapies provides a broader competitive moat.